← All trials
NCT06228586
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 18, 2024
- Primary completion
- Mar 31, 2024
- Completion date
- Mar 31, 2024
- First posted
- Jan 29, 2024
- Last posted
- May 24, 2024
- Enrollment
- 446
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sanofi-AventisLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.